Validation of a Predictive Score of Acute Chest Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vaso-Occlusive Crisis (VOC), the most common manifestation of sickle cell disease (SCD), is the first cause of death, particularly when complicated by an acute chest syndrome (ACS).

The PRESEV score could help the physicians to better manage VOC and could be used for future therapeutic trials. This predictive score of secondary ACS has to be validated in a multicenter international study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

International multicentre prospective observational study.

Prediction of an ACS within 15 days after admission by the PRESEV2 score at arrival.

Validation of a Predictive Score of Acute Chest Syndrome (Presev2) associates a categorical pain score of the spine /or pelvis and 3 biological parameters: Reticulocytes, Leucocytes and Hemoglobin.

ACS is defined by crepitant or bronchial breathing or the association of new radiologic infiltrate and chest pain

Inclusion criteria:

* Children (\>2 years) and adults
* Male and Female
* Homozygous SCD patients
* The patient can only be included once
* VOC admitted at the emergency unit (a severe VOC is defined as pain or tenderness affecting at least one part of the body (e.g. limbs, ribs, sternum, head (skull), spine and/or pelvis) that required hospitalization and opioids (level 3), and is not attributable to other causes.
* Patient has health care insurance (in Europe)
* Written consent given after being informed of the purpose, progress and potential risks

Exclusion criteria:

* No inaugural Acute Chest Syndrome
* Homeless patients
* Deprived of their liberty by a court or administrative order or under guardianship
* Unable to understand the purpose and conditions of carrying out the study, unable to give consent

STUDY SCHEDULE Screening and inclusion once patients are admitted at the accident and emergency department or medical day unit.

Inclusion visit (day 1) Once admitted at the accident and emergency department, the patient will be informed about the protocol and asked to participate in the study. Informed consent will be obtained according to local regulations by signing the informed consent form. The inclusion and non-inclusion criteria will be verified.

Demographic data, current and previous treatments taken within one month, and medical history will be recorded.

The following parameters of the score will be collected:

Reticulocytes and/or leucocytes counts, urea (mmol/L) and Categorical pain score.

The Score is adjusted with Hydroxyurea treatment (Yes/No) and Hb level (g/dL). Plasmodium falciparum test will be performed only in Africa. Hemoculture if fever (\>38°C) is recorded within the 2 first days after admission.

Temperature, Blood pressure, Oxygen saturation, Respiratory rate, Visual analogue score will be recorded.

STUDY DURATION Inclusion period: 2 years Per patient: 15 days Total duration of the study: 2 years

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaso Occlusive Crisis Acute Chest Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

sickle cell desease vaso occlusive crisis acute chest syndrome Validation of predictif score of acute chest syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VOC

Patients who won't develop a secondary Acute chest syndrome during a vaso occlusive crisis within 15 days after admission.

Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate and chest pain or decreased breath sounds .

A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults. It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries.

No interventions assigned to this group

2°ACS

Patients who will develop a secondary acute chest syndrome during a vaso occlusive crisis within 15 days after admission.

Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate AND chest pain or decreased breath sounds .

A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults.It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children (\>2 years) and adults
* Male and Female
* Homozygous SCD patients
* VOC admitted at the emergency unit (a severe VOC is defined as pain or tenderness affecting at least one part of the body (e.g. limbs, ribs, sternum, head (skull), spine and/or pelvis) that required hospitalization and opioids (level 3), and is not attributable to other causes.
* Patient has health care insurance (in Europe)
* Written consent given after being informed of the purpose, progress and potential risks

Exclusion Criteria

* No inaugural Acute Chest Syndrome
* Homeless patients
* Deprived of their liberty by a court or administrative order or under guardianship
* Unable to understand the purpose and conditions of carrying out the study, unable to give consent

Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

BARTOLUCCI Pablo, MD PhD, Pr

Role: PRINCIPAL_INVESTIGATOR

APHP, UPEC, INSERM

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Henri Mondor Hospital

Créteil, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

DJOUMAD Sabrina, Master's

Role: CONTACT

Phone: 33 (1) 49812441

Email: [email protected]

BERKENOU Jugurtha, Master's

Role: CONTACT

Phone: 33 (1) 49814414

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pablo BARTOLUCCI, Professor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Presev 2 IRB 00003835

Identifier Type: -

Identifier Source: org_study_id